Beam Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M | $51.8M |
| Operating income | -$383.7M | -$415.6M | -$176.5M | -$338.5M | -$392.5M |
| Operating expenses | $523.4M | $479.1M | $554.2M | $399.4M | $444.3M |
| Cash from operations | -$345.1M | -$347.2M | -$149.2M | $22.5M | -$66.3M |
| Capital expenditure | $14.9M | $8.9M | $33.7M | $49.0M | $46.8M |
| Free cash flow | -$360.0M | -$356.2M | -$182.9M | -$26.4M | -$113.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $1.5B | $1.1B | $1.5B | $1.3B | $1.5B |
| Total liabilities | $242.8M | $370.3M | $478.4M | $608.2M | $647.7M |
Shares outstanding 102.9M · Free float 95.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.